Website: pando.bio   |   LinkedIn: https://www.linkedin.com/company/pando-bioscience/

Better Enzymes, Designed by AI

How Pando Bioscience combines generative AI and high-throughput screening to engineer enzymes for pharma and diagnostics

At a glance

  • Company: Pando Bioscience (pando.bio)
  • Headquarters: Watertown, Massachusetts
  • Founded: 2022, Y Combinator W23
  • Focus: AI-driven enzyme engineering for pharmaceutical manufacturing, diagnostics, and life science tools
  • Working with PSG on: Sales and business development scaling

Enzymes are leaving value on the table

Enzymes power everything from drug manufacturing to molecular diagnostics. But most of the enzymes in use today were never optimized for the jobs they do, and traditional engineering is slow, testing just a handful of variants per cycle.

Pando was built to change that.

AI plus experiments, at scale

Pando pairs generative AI models with high-throughput experimental screening, so each design cycle teaches the model something new. Its one-pot screening approach evaluates vastly more variants per round than traditional methods. And because Pando trains its models on its own experimental data, the company reports hit rates far higher than models trained only on public databases.

The result: enzymes that are more efficient, more robust, and more cost-effective, delivered faster.

Built for industry

  • Pharmaceutical manufacturing: biocatalysts that improve yield, selectivity, and process economics
  • Diagnostics: enzymes optimized for performance and reliability in assays
  • Life science tools: better-performing enzymes for molecular biology workflows
  • Partnered engineering: custom enzyme discovery and optimization programs for pharma, diagnostic, and biotech teams

Pando was selected for Y Combinator’s Winter 2023 batch and the Creative Destruction Lab’s Advanced Therapies stream.